Printer Friendly

Fujirebio Diagnostics Promotes Peter Minetti to Vice President of Quality and Regulatory Compliance.

MALVERN, Pa. -- Fujirebio Diagnostics, Inc. (FDI), a world-leader in oncology testing, has promoted Peter L. Minetti to vice president of Quality and Regulatory Compliance. Minetti is responsible for implementing and maintaining corporate quality standards and for developing policies, procedures and methods to ensure that all products manufactured and distributed by FDI meet quality and regulatory requirements.

"Pete has more than 30 years of industry experience, including five within our organization as director of Quality and Regulatory Compliance," said Paul Touhey, president and chief operating officer at FDI. "Pete's attention to detail, work ethic, and leadership have resulted in FDI's outstanding results in product quality and GMP and ISO compliance. Pete has led the continuous improvement in our Quality Systems."

Minetti joined FDI in 2000 and assumed responsibility for managing all elements of FDI's quality system. In this role, he built, implemented and manages a quality system that complies with the FDA's Quality System Regulation, and achieved certification for meeting ISO9001/13485 standards.

Prior to FDI, Minetti served as Manager of Quality Assurance (QA), Quality Control (QC) and Regulatory Affairs (RA) for Biopool International. For more than 13 years previous, he worked at Organon Teknika, where he held various management positions, including QA, QC and RA Manager, and Manufacturing Manager. Minetti also managed manufacturing, distribution, data processing and regulatory compliance for Coulter Immunology, and served in numerous management and technical capacities with Pfizer Inc.'s Diagnostics Division, with J&J's Ortho Diagnostics subsidiary, and with the United States Public Health Service.

Minetti holds certifications from the American Society for Quality (ASQ) for Quality Manager (CQMgr), Quality Engineer (CQE) and Quality Auditor (CQA), and from the American Production and Inventory Control Society (APICS) in Production and Inventory Management (CPIM) and Integrated Resource Management (CIRM). Minetti earned a Bachelor of Science degree from City College of New York.

About FDI

Fujirebio Diagnostics, Inc. (FDI) is a premier diagnostics company and the industry leader in tumor marker assays. FDI specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. In November 1998, Fujirebio, Inc. of Tokyo, Japan, acquired the company, formerly known as Centocor Diagnostics. FDI utilizes its worldwide distribution network to enable access by physicians and patients to its diagnostic products. For more information about FDI, please call 610-240-3800 or visit
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 22, 2005
Previous Article:FuseMail Announces Innovative Webmail Application; FuseMail v2.0 Bridges Gap between Web and Desktop e-Mail.
Next Article:Stedman's Introduces New 2005 Premium and Standard Editions of Its Renowned Medical and Pharmaceutical Spellchecker.

Related Articles
People in the News.
Government agencies consider adopting ISO 14000 standards. (Industry Viewpoint).
A comparison of ten serological tumor markers for the detection of gastric cancer.
Fujirebio Diagnostics, Inc. Appoints Dr. W. Jeffrey Allard Vice President and Chief Scientific Officer.
Sanko Junyaku, Eisai and Fujirebio Sign Joint Research Agreement for Development of New KL-6 Test Kit.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters